These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 30234392)

  • 1. The dawn of precision medicine in HIV: state of the art of pharmacotherapy.
    Mu Y; Kodidela S; Wang Y; Kumar S; Cory TJ
    Expert Opin Pharmacother; 2018 Oct; 19(14):1581-1595. PubMed ID: 30234392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of the pharmacogenetics of HIV therapy.
    Rodríguez-Nóvoa S; Barreiro P; Jiménez-Nácher I; Soriano V
    Pharmacogenomics J; 2006; 6(4):234-45. PubMed ID: 16462814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries.
    De Luca A; Hamers RL; Schapiro JM
    J Infect Dis; 2013 Jun; 207 Suppl 2():S63-9. PubMed ID: 23687291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.
    Neely MN; Rakhmanina NY
    Clin Pharmacokinet; 2011 Mar; 50(3):143-89. PubMed ID: 21294595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision medicine for HIV: where are we?
    Cusato J; Allegra S; Nicolò A; Calcagno A; D'Avolio A
    Pharmacogenomics; 2018 Jan; 19(2):145-165. PubMed ID: 29202676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rolling out Efavirenz for HIV Precision Medicine in Africa: Are We Ready for Pharmacovigilance and Tackling Neuropsychiatric Adverse Effects?
    Masimirembwa C; Dandara C; Leutscher PD
    OMICS; 2016 Oct; 20(10):575-580. PubMed ID: 27627692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)].
    Iribarren JA; Labarga P; Rubio R; Berenguer J; Miró JM; Antela A; González J; Moreno S; Arrizabalaga J; Chamorro L; Clotet B; Gatell JM; López-Aldeguer J; Martínez E; Polo R; Tuset M; Viciana P; Santamaría JM; Kindelán JM; Ribera E; Segura F; ;
    Enferm Infecc Microbiol Clin; 2004 Dec; 22(10):564-642. PubMed ID: 15596051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project.
    Andreoni M; Marcotullio S; Puro V; De Carli G; Tambussi G; Nozza S; Gori A; Rusconi S; Santoro MM; Clementi M; Perno CF; d'Arminio Monforte A; Maggiolo F; Castagna A; De Luca A; Galli M; Giacomelli A; Borderi M; Guaraldi G; Calcagno A; Di Perri G; Bonora S; Mussini C; Di Biagio A; Puoti M; Bruno R; Zuccaro V; Antinori A; Cinque P; Croce D; Restelli U; Rizzardini G; Lazzarin A
    New Microbiol; 2015 Oct; 38(4):443-90. PubMed ID: 26571377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update and review of antiretroviral therapy.
    Piacenti FJ
    Pharmacotherapy; 2006 Aug; 26(8):1111-33. PubMed ID: 16863488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of antiretroviral drug resistance.
    Wainberg MA; Zaharatos GJ; Brenner BG
    N Engl J Med; 2011 Aug; 365(7):637-46. PubMed ID: 21848464
    [No Abstract]   [Full Text] [Related]  

  • 11. New antiretroviral drugs, part II: NRTIs, NNRTIs, and beyond.
    Murphy RL
    AIDS Clin Care; 1999 Jun; 11(6):47-9, 51, 53-4. PubMed ID: 11366882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic Markers: A Path toward Individualized HIV Therapy.
    García-Blanco D; Gravier-Hernández R; Rabeiro-Martínez CL; Gil Del Valle L; Pérez-Ávila J
    MEDICC Rev; 2019; 21(2-3):59-68. PubMed ID: 31401638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dolutegravir for the treatment of HIV.
    Katlama C; Murphy R
    Expert Opin Investig Drugs; 2012 Apr; 21(4):523-30. PubMed ID: 22380682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological considerations on the use of antiretrovirals in pregnancy.
    Colbers A; Greupink R; Burger D
    Curr Opin Infect Dis; 2013 Dec; 26(6):575-88. PubMed ID: 24152762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China.
    Chen J; Zhang M; Shang M; Yang W; Wang Z; Shang H
    BMC Infect Dis; 2018 Nov; 18(1):571. PubMed ID: 30442114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New antiretroviral agents and the complexity of treatment practices.
    Smith D
    J HIV Ther; 2008 Jun; 13(2):25-6. PubMed ID: 18953270
    [No Abstract]   [Full Text] [Related]  

  • 18. Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients.
    Jiménez-Nácher I; Alvarez E; Morello J; Rodriguez-Nóvoa S; de Andrés S; Soriano V
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):457-77. PubMed ID: 21342079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.
    Calcagno A; Cusato J; D'Avolio A; Bonora S
    Clin Pharmacokinet; 2017 Apr; 56(4):355-369. PubMed ID: 27641153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.